SynopsisAcral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. The global Acral Lentiginous Melanoma Drugs market was valued at.....
SynopsisAcral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. The global Acral Lentiginous Melanoma Treatment market was value.....
SynopsisAcral Lentiginous Melanoma Drugs, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. The global Acral Lentiginous Melanoma market was valued at US$ 6.....
SynopsisOctreotide (trade name Sandostatin, among others) is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. The global Sandostatin LAR mar.....
SynopsisPasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. The global Pasireotide market was valued at US$ 104.5 million in 2023 and is antici.....
SynopsisSignifor is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. The global Signifor market was valued at US$ 104.5 million in 2023 and is anticipated .....
SynopsisLanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome The global Lanreotide market was valued at US$ 1401 million in 2023 and is anticipated to reach US$ 1506.5.....
SynopsisSomatuline is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome The global Somatuline market was valued at US$ 1401 million in 2023 and is anticipated to reach US$ 1506.5 milli.....
SynopsisOctreotide (trade name Sandostatin, among others) is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. The global Sandostatin LAR Dru.....
SynopsisPasireotide is an orphan drug approved in the United States and Europe for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. The global Pasireotide Drugs market was valued at US$ 104.5 million in 2023 and is .....
